

Fund description

The Fiducian Technology Fund allows investors to participate directly in a blend of some of the leading technology funds available worldwide. Utilising the Fiducian “Manage the Manager” process, fund managers have been chosen to balance exposure in terms of region and sector.

Managers are able to invest in technology companies anywhere in the world that can benefit from leading-edge technology and can demonstrate significant earnings growth prospects.

Investors must bear in mind that investing in a fund of this nature can involve periods of very high volatility, although superior long-run returns can likely be achieved if investors are prepared to hold investments for periods of at least 9 years.

Fund facts

Portfolio manager: Conrad Burge

ARSN: 093 544 337

APIR code: FPS0010AU

Benchmark: NASDAQ-100 Index (AUD)

Current fund size: \$254 million (February 2025)

Management cost: 1.36%

Total management costs: 1.42%

Application/Exit fee: Nil

Inception Date: June 2000

Manager	Style			Sector		
	Value	Core	Growth	IT	Biotech	Blend
Wellington Tech		●		●		
Wellington Biotech		●			●	
Invesco Nasdaq 100 ETF	●			●		
ABG Nordic			●			●
Loftus Peak			●	●		


Performance and Risk

After fee returns as at 28 February 2025

	1 Mth	3 Mth	6 Mth	1 Yr	3 Yrs	5 Yrs	7yrs	10 Yrs
Fund	-4.6%	3.1%	11.3%	16.3%	7.4%	9.2%	11.5%	12.9%
Index	-2.4%	4.7%	16.7%	21.9%	18.1%	14.6%	15.4%	14.0%
Excess	-2.1%	-1.6%	-5.5%	-5.5%	-10.7%	-5.3%	-3.9%	-1.1%



Risk Exposure

	1 Yr	3 Yrs	5 Yrs	10 Yrs
Fund Volatility (Std Dev %)	12.0%	16.4%	16.2%	15.7%
Benchmark (Std Dev %)	11.7%	12.9%	13.6%	13.3%
Beta	0.90	1.07	1.01	1.02
Tracking Error (% pa)	3.4%	8.3%	8.2%	7.7%



*Prior to 31 Dec 23, the benchmark for the Fund was 50/50 MSCI World IT (AUD)/NASDAQ Biotechnology (AUD)

Geographic exposures and current manager weights



Market Commentary and Outlook

The global economy has continued to sustain solid growth despite the persistence of tight monetary policy being implemented by most of the world's major central banks in an effort to push inflation lower and back into target ranges. The latest report from the International Monetary Fund (IMF) noted that while global disinflation continues, it remains elevated in a few cases. Nonetheless, interest rates have continued to trend downwards, with the US central bank and the European Central Bank both lowering rates in recent months, although rate cuts may be paused for a time given recent high inflation data.

While US President Donald Trump returned to government with policies aimed at stimulating economic growth and productivity, concerns over tariffs and a growth slowdown saw the broad US stock market (S&P 500 Accumulation Index) decrease 1.3% over the month while the Australian market (ASX 200 Accumulation Index) fell 3.8%. Domestic and global bonds recorded positive returns over the same period. Commodity prices were mixed, with gains in gold, copper and iron ore, but coal and oil prices declined.

For some time now, key global share markets have been 'pricing-in' a shift by central banks towards less restrictive monetary policy, which has led to strong returns for equity investors. However, geopolitical risks remain heightened and continue to represent potential headwinds. Despite this, the IMF is forecasting global economic growth to be 3.3% in both 2025 and 2026, which is close to its long-term trend rate. In broad terms, share markets continue to appear more attractive than most other investment opportunities.

Fund Commentary

The Fiducian Technology Fund declined 4.6% in February, which was below the index return of -2.4%. For the 12 months to the end of February, the Fund returned 16.3%.

Technology stocks were lower in February, with the NASDAQ 100 index declining 2.4%, which underperformed the broader US stock market which declined by 1.3% (both in US Dollars).


The outlook for the US economy remains the primary driver of market performance. Markets are expecting the new Trump administration, with the help of a Republican majority Congress, to implement a pro-growth agenda, including further tax cuts and significant deregulation, that could be positive for the economy. However, inflation remains relatively elevated, which could imply that interest rates may not decline as rapidly as markets have been 'pricing in'.

The longer-term outlook for the technology sector remains positive, as the need to invest in innovation to drive productivity gains across areas such as artificial intelligence, manufacturing, life sciences and sustainable energy should prove to be structural tailwinds for technology companies. Moreover, the sector may continue to benefit from favourable sentiment surrounding the outlook for Artificial Intelligence (AI), despite recent short-term corrections.

The Fund remains well diversified between geographies and sectors, and companies held are a blend of established sector leaders plus emerging technology businesses. An overweight position in the Information Technology sector relative to Biotechnology reflects the better growth opportunities currently available in that part of the market. The largest geographical exposure is to North America which makes up 91.6% of the fund, followed by Asia at 4.2%.

Top stock holdings and sector weights

Stock	Industry	Weight
Nvidia Corp	Semiconductors	9.8%
Taiwan Semiconductor	Semiconductors	5.9%
Amazon.Com	Internet	5.9%
Microsoft Corp	Software	5.5%
Broadcom	Semiconductors	4.4%
Apple Inc	Computers	3.9%
Netflix Inc	Internet	3.5%
Meta Platforms	Internet	2.9%
Mastercard	Finance - Credit Card	2.8%
Alphabet	Internet	2.5%



Fiducian Investment Management Services Limited

Issued by Fiducian Investment Management Services Limited ABN 28 602 441 814 AFS Licence number 468211. This document provides general information only. It does not have regard to your objectives, financial situation or needs. We recommend that you seek financial planning advice, and consider whether this investment is appropriate to your objectives, financial situation and needs before making any investment decision.

The information has been compiled from sources considered reliable, but is not guaranteed. Past performance is not indicative of future performance and we do not guarantee the performance of the Fund or any specific rate of return. Potential investors should also obtain and consider the relevant Target Market Determination (TMD) and Product Disclosure Statement (PDS) (available from your financial adviser and via fiducian.com.au) before making a decision about whether to acquire or continue to hold any financial product.